Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France.
Bonnet I, Haddad E, Guglielmetti L, Bémer P, Bernard L, Bourgoin A, Brault R, Catho G, Caumes E, Escaut L, Fourniols E, Fréchet-Jachym M, Gaudart A, Guillot H, Lafon-Desmurs B, Lanoix JP, Lanotte P, Lemaignen A, Lemaire B, Lemaitre N, Michau C, Morand P, Mougari F, Marigot-Outtandy D, Patrat-Delon S, Perpoint T, Piau C, Pourcher V, Zarrouk V, Zeller V, Veziris N, Jauréguiberry S, Aubry A; CRIOAC Pitié-Salpêtrière and the TB Consilium of the National Reference Center for Mycobacteria. Bonnet I, et al. Among authors: pourcher v. Microorganisms. 2022 Jun 14;10(6):1215. doi: 10.3390/microorganisms10061215. Microorganisms. 2022. PMID: 35744731 Free PMC article.
Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium.
Guglielmetti L, Jaffré J, Bernard C, Brossier F, El Helali N, Chadelat K, Thouvenin G, Dautzenberg B, Henry B, Jaspard M, Guillot H, Pourcher V, Le Dû D, Marigot-Outtandy D, Mougari F, Raskine L, Rivoire B, Andrejak C, Jarlier V, Aubry A, Robert J, Frechet-Jachym M, Veziris N. Guglielmetti L, et al. Among authors: pourcher v. Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1050-1054. doi: 10.5588/ijtld.18.0779. Int J Tuberc Lung Dis. 2019. PMID: 31627768
The First Locally Acquired Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Healthcare Worker in the Paris Area.
Klement E, Godefroy N, Burrel S, Kornblum D, Monsel G, Bleibtreu A, Marcelin AG, Calvez V, Caumes E, Boutolleau D, Pourcher V. Klement E, et al. Among authors: pourcher v. Clin Infect Dis. 2020 Dec 3;71(9):e530-e531. doi: 10.1093/cid/ciaa171. Clin Infect Dis. 2020. PMID: 32211789 Free PMC article. No abstract available.
Reply to Million et al.
Hajage D, Pourcher V, Paccoud O, Bleibtreu A, Caumes E, Tubach F. Hajage D, et al. Among authors: pourcher v. Clin Infect Dis. 2021 May 4;72(9):e440-e441. doi: 10.1093/cid/ciaa1122. Clin Infect Dis. 2021. PMID: 32761119 No abstract available.
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabié A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy study group. Ader F, et al. Among authors: pourcher v. Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26. Clin Microbiol Infect. 2021. PMID: 34048876 Free PMC article. Clinical Trial.
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Ader F, et al. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14. Lancet Infect Dis. 2022. PMID: 34534511 Free PMC article. Clinical Trial.
135 results